Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT03501680
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Registry
-
NCT03501680
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT03501680. Randomized; no masking; primary purpose treatment. Start 2018-06-06 (anticipated); primary completion 2020-03-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.
- Acronym
- HAPinsulin
- Condition
- Acute Pancreatitis
- Condition
- Hypertriglyceridemia
- Intervention (Drug)
- Insulin
- Intervention (Device)
- plasmapheresis
- Lead sponsor
- First Affiliated Hospital of Wenzhou Medical University
Record details
- Record id
cardio:ct-nct03501680- Content hash
7739220fbcdec8fcf813b89d42c5ff4d7c57c861d670007c199f0cf81d87aef8